2004
DOI: 10.1016/j.vaccine.2004.01.032
|View full text |Cite
|
Sign up to set email alerts
|

Immunisation against PCV2 structural protein by DNA vaccination of mice

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
36
0

Year Published

2005
2005
2020
2020

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 60 publications
(38 citation statements)
references
References 22 publications
2
36
0
Order By: Relevance
“…It is conceivable that the delay in replication translates into attenuation in vivo, leading to a virus strain with vaccine potential. For PCV2, ORF2 protein has been considered as a major immunogenic capsid protein (9,30,31) and could stimulate a protective response in pigs inoculated with baculovirus-expressed recombinant ORF2 (5) or injected with DNA vaccine from ORF2 (5,19). Chimeric PCV1-2 virus with the ORF2 gene of PCV2 cloned into the nonpathogenic PCV1 genomic backbone could also induce a strong immune response against PCV2 while it is mildly pathogenic (15), suggesting that the ORF2 protein of PCV2 is a good host-protective immunogen.…”
Section: Discussionmentioning
confidence: 99%
“…It is conceivable that the delay in replication translates into attenuation in vivo, leading to a virus strain with vaccine potential. For PCV2, ORF2 protein has been considered as a major immunogenic capsid protein (9,30,31) and could stimulate a protective response in pigs inoculated with baculovirus-expressed recombinant ORF2 (5) or injected with DNA vaccine from ORF2 (5,19). Chimeric PCV1-2 virus with the ORF2 gene of PCV2 cloned into the nonpathogenic PCV1 genomic backbone could also induce a strong immune response against PCV2 while it is mildly pathogenic (15), suggesting that the ORF2 protein of PCV2 is a good host-protective immunogen.…”
Section: Discussionmentioning
confidence: 99%
“…15 A BALB/c mouse model has also been used to test a plasmid PCV2 DNA coated onto gold particles. 53 Commercial PCV2 vaccines for use in growing pigs and breeding-age animals became available in North America in 2006 (Table 6). Evidence to date indicates that the commercial vaccines are a remarkably effective tool to reduce losses in herds and production systems experiencing PCVAD in growing pigs.…”
Section: Control Of Coinfectionsmentioning
confidence: 99%
“…tested (mean log PCV2 load±SD) at the following weeks p.c. 2004; Ju et al, 2005;Kamstrup et al, 2004;Song et al, 2007;Wang et al, 2006Wang et al, , 2007. In the present study, we investigated the Cap-specific lymphoproliferative activity and splenocyte phenotypes induced by different immunization protocols.…”
Section: Groupmentioning
confidence: 99%
“…Based on comparison of the immunogenicity of the PCV2 Cap and Rep proteins, Blanchard et al (2003) demonstrated that the ORF2-encoded Cap protein was the major immunogen, whilst the ORF1-encoded Rep protein was only weakly immunogenic. Kamstrup et al (2004) subsequently investigated the potential of a DNA vaccine encoding the PCV2 Cap protein in mice and demonstrated the production of antibody. On the other hand, Fenaux et al (2003Fenaux et al ( , 2004 focused on a chimeric PCV1-PCV2, which was shown to induce specific antibody responses and protection against PCV2 in pigs.…”
Section: Introductionmentioning
confidence: 99%